CAJ | 학술논문

目的：探讨不同临床特征的肾癌患者并发静脉血栓比例，为肾癌并发静脉血栓的风险评估提供临床依据。方法：收治肾癌并发静脉血栓患者51例，分别记录不同年龄、性别、分期、病理类型、ECOG评分阶段中发生静脉血栓患者数量及实验室检查指标在伴有静脉血栓者和无静脉血栓者的分布情况，进行统计学分析。结果：①患者年龄与静脉血栓形成概率呈正相关(P=0.004)，当年龄≥60.2岁患者并发静脉血栓风险显著增加(P=0.005)。②ECOG评分≤2分者静脉血栓发生率明显高于ECOG评分＞2分者，差异具有统计学意义(P=0.001)。③发生静脉血栓者纤维蛋白原水平明显高于无静脉血栓者，差异具有统计学意义(P=0.006)。结论：年龄≥60.2岁、ECOG评分≤2分、纤维蛋白原水平升高是初治肾透明细胞癌患者并发静脉血栓的高危因素。
목적：탐토불동림상특정적신암환자병발정맥혈전비례，위신암병발정맥혈전적풍험평고제공림상의거。방법：수치신암병발정맥혈전환자51례，분별기록불동년령、성별、분기、병리류형、ECOG평분계단중발생정맥혈전환자수량급실험실검사지표재반유정맥혈전자화무정맥혈전자적분포정황，진행통계학분석。결과：①환자년령여정맥혈전형성개솔정정상관(P=0.004)，당년령≥60.2세환자병발정맥혈전풍험현저증가(P=0.005)。②ECOG평분≤2분자정맥혈전발생솔명현고우ECOG평분＞2분자，차이구유통계학의의(P=0.001)。③발생정맥혈전자섬유단백원수평명현고우무정맥혈전자，차이구유통계학의의(P=0.006)。결론：년령≥60.2세、ECOG평분≤2분、섬유단백원수평승고시초치신투명세포암환자병발정맥혈전적고위인소。
Objective:To investigate the proportion of combined with venous thrombosis in patients with renal cell carcinoma with different clinical characteristics,and to provide the clinical basis for the risk assessment of renal cell carcinoma patients with venous thrombosis.Methods:51 renal cell carcinoma patients with venous thrombosis were selected.We respectively recorded the number of patients with venous thrombosis in different age,gender,pathological type,stage,ECOG score and distribution situation of patients with or without venous thrombosis in index of laboratory examination,we made a statistical analysis.Results:①The age of patients was positively related to the probability of forming venous thromboembolism(P=0.004),when more than 60.2 years old, the risk of patients with venous thrombosis was significantly increased(P=0.005).②In patients with ECOG score less than 2 points, venous thrombosis incidence was significantly higher than that of ECOG score more than 2 points,the difference was statistically significant(P=0.001).③In patients with venous thrombosis,fibrinogen level was significantly higher than those without venous thrombosis,the difference was statistically significant (P=0.006).Conclusion:More than 60.2 yearsold,ECOG score less than 2 points,the higher level of fibrinogen were risk factors for renal clear cell carcinoma patients complicated with venous thrombosis.